Prescribed Product Disclosures

January 1, 2012 – December 31, 2012

Report of

Vermont Attorney General

William H. Sorrell

October 2013

Prepared by staff of the Vermont Attorney General's Office:

Wendy Morgan, Assistant Attorney General

Kate Whelley McCabe, Assistant Attorney General

AJ Van Tassel, Investigator

Ginni Lavely, Legal Assistant

Prescribed Product Disclosures:

Report of Vermont Attorney General William H. Sorrell for Calendar Year 2012

October 2013

I. Summary

This is the eleventh report of Vermont Attorney General William H. Sorrell on Prescribed Product Disclosures. It is based upon disclosures of activity engaged in during the period of January 1, 2012, through December 31, 2012[1] by manufacturers of pharmaceutical, biologic (e.g., vaccines) and medical device products (e.g., artificial hip, upper extremity prosthesis, hearing aid, scopes). Vermont's Prescribed Product Disclosure Law, 18 V.S.A. §§ 4631a, 4632, requires the Vermont Attorney General to issue an annual report about the disclosures.[2]

This report reflects some recent amendments made to Vermont's law in 2009 and 2011. Most notably, the report reflects the 2009 amendment requiring manufacturers to disclose information regarding the distribution of samples of prescribed products to health care providers in addition to expenditures and gifts (hereinafter, expenditures and gifts are referred to collectively as "expenditures"). Finally, the report reflects two 2011 changes: one requiring manufacturers to report information about the distribution of over-the-counter product; the other exempting manufacturers of prescription eyewear from having to report.

Samples disclosures may only be reported to the public in aggregate form. Thus, while expenditure disclosures have been posted along with this report on the Attorney General's Website: www.atg.state.vt.us, samples disclosures have not.

As always, changes in the law complicate the comparison of data from year to year. However, amendments have been accounted for in the summary below and in the accompanying tables to the extent possible. Note that because manufacturers are not required to disclose the dollar value of samples, dollar values continue to reflect expenditures only; samples are reported only by quantity.

Manufacturers, Expenditures and Samples

[1] Until 2012, manufacturers disclosed expenditures and gifts by fiscal year (July 1 through June 30 of the next calendar year). The 2011 report reflected the transition to reporting by calendar year, which is the schedule for reporting to the federal government under the Physician Payments Sunshine Provision (§ 6002) of the Patient Protection and Affordable Care Act (Pub. L. No. 11-148), by combining data from the last six months of the FY11 reporting period (January 1, 2011 through June 30, 2011), and the entire six-month 2011 reporting period (July 1, 2011 – December 31, 2011). The Attorney General chose to report on a twelve month period of expenditure and gift disclosures, notwithstanding the truncated 2011 reporting period, in order to facilitate comparison with prior, and future, reporting years.

[2] The information that forms the basis of this report comes solely from the disclosures of prescribed product manufacturers; the recipients of the disclosed gifts, expenditures, and samples have not had the opportunity to review the disclosures or confirm their accuracy. Moreover, by publishing the disclosures, the Attorney General makes no representation as to their accuracy or the legality of the underlying conduct.

According to the disclosures corresponding to the activity that took place in calendar year 2012, 187 manufacturers reported spending approximately 7.6 million dollars and distributing nearly 73,000 samples to Vermont health care providers, institutions and organizations.[3] Only 18 manufacturers had expenditures greater than $100,000, and 132 manufacturers had either expenditures of less than $20,000 or no expenditures at all. Only 7 manufacturers distributed 3,000 or more samples, and 105 manufacturers disclosed no sample activity at all. Exhibits 1a and 1b.

Expenditures on pharmaceutical products accounted for more than 5.3 million dollars of the 7.6 million dollar expenditure total, and were made by 75 manufacturers. Thus, 40% of the manufacturers accounted for more than 70% of expenditures. Exhibits 3 and 4.

As in years past, expenditures for pharmaceuticals dominated the percent of total dollars reported (62% as compared with 18% for medical devices and 14% for biologic products). However, for the third reporting period in a row, more than half of the total number of expenditures were associated with medical devices (59% as compared with 34% for pharmaceuticals and 5% for biologic products). Exhibit 2.

Pharmaceuticals also dominated the percent of the total number of samples distributed (87% as compared with 11% for medical devices and 0.1% for biologic products). Exhibit 2.

The 2012 pharmaceutical expenditure total of more than 5.3 million dollars may appear to exceed even the highest annual level of spending reported in FY04. However, excluding payments made on clinical trials and research, expenditures which were not reported until FY10, puts 2012 expenditures at approximately 1.2 million dollars, the lowest level of pharmaceutical marketing expenditures reported in FY04 through 2012. Exhibit 3.

Of the 187 disclosing manufacturers, 83 reported expenditures of exclusively medical devices and biologics, and 29 reported only sample distribution. Exhibit 4.

The number of manufacturers reporting pharmaceutical expenditures for 2012 (75) dropped from the level reported in 2011 (77), as did the number of manufacturers that reported expenditures related exclusively to non-pharmaceutical products (83 in 2012 as compared with 104 in 2011) and the total number of manufacturers reporting expenditures (158 in 2012 as compared with 181 in 2011). The total number of expenditures also dropped to 5,059 in 2012 from 6,179 in 2011. The 5,059 figure represents a 68% decrease from a high of 15,880 expenditures in FY08, and constitutes only about 7% of the incidence of expenditures and samples in 2012 combined. In other words, roughly 93% of all 2012 reports were for samples; this figure is consistent with 2012, in which 94% of all reports were for samples. Exhibits 4 and 5.

Pfizer was the only manufacturer among both the five manufacturers with the highest total expenditure dollars and the five manufacturers with the highest sample distribution during 2012; Pfizer had the second highest expenditure dollar total, and the fourth highest sample total. The five manufacturers with the highest total expenditure dollars during 2012 were: (1) Eli Lilly, (2) Pfizer, (3) Genentech, (4) Forest Laboratories, and (5) Merck, Sharp & Dhome. The five

[3] In 2012, 158 manufacturers reported having made $7,629,644.67 in expenditures, and 82 manufacturers reported having distributed 72,755 samples.

manufacturers with the highest sample distribution during 2011 were: (1) AstraZeneca, (2) GlaxoSmithKline, (3) Eli Lilly, (4) Pfizer, and (5) Forest Pharmaceuticals (a subsidiary of Forest Laboratories). Exhibit 6.

The percentage of samples reported by the top five manufacturers by samples distribution, as compared with the total number of samples reported was 49% as compared with 44% in 2011. Similarly, the five manufacturers with the greatest expenditure dollars in 2012 account for 47% of total expenditure dollars as compared with 45% in 2011. Both the 2011 and 2012 expenditure figures are consistent with levels reported in FY09 and FY10; in FY09 and FY10, the top five manufacturers by expenditure dollars were responsible for 47% of total expenditure dollars, a decrease from prior levels of 52% (FY08) and 56% (FY07). Exhibit 6.

Recipients

Approximately 66% of the dollar value of expenditures made in 2012, or 5 million dollars, went to clinical trials and research. Of the balance, recipients of the highest percentage of expenditure dollars in 2012 were doctors and recipients in the aggregate[4] (11% each), hospitals or clinics (5% total) and academic institutions (4%). Exhibit 7.

Roughly 77% of samples distributed in 2012 went to doctors. Of the balance, recipients of the highest percentage of samples distributed in 2012 were reported as having been received by other health care providers and other prescribers (9% each) and pharmacies, pharmacists or pharmacy technicians (4% total). Exhibit 7.

Excluding expenditures made in connection with clinical trials, the number of health care providers receiving $3,000 or more dropped from 65 in 2011 to 60 in 2012. However, this figure still represents an increase of 36% from the corresponding FY10 figure (44). In contrast, the total dollars received by this group dropped to approximately $900,000 from 1.3 million dollars in 2011, a 31% decrease in just one year. A total of 43 health care providers received 250 or more samples in 2012, a figure 17% lower than the 52 in 2011. Exhibits 8a and 8b.

The greatest amount of expenditures to the 50 health care providers who received $3,000 or more in 2012 went to doctors specializing in cardiovascular disease, for a total of over $125,000. In addition to this group, health care providers who received $3,000 or more individually and over $50,000 as a group were doctors identifying their specialties as orthopedic surgery, internal medicine and emergency medicine. The greatest amount of samples to the 43 health care providers who received 250 or more samples went to doctors specializing in internal medicine. In addition to this group, health care providers who received 250 or more samples individually and more than 500 as a group were doctors identifying their specialties as family practice, critical care medicine and cardiovascular disease, as well as physician assistants and advanced practice registered nurses. Exhibits 8a and 8b.

Excluding expenditures associated with clinical trials, the largest amount of expenditures associated with any single individual recipient in 2012 was approximately $126,000 to a doctor

[4] The Attorney General's Office allows manufacturers to elect to report permitted gifts with a fair market value below $25 as having gone to all Vermont health care providers and institutions in the aggregate. The overwhelming majority of aggregate spending is related to educational materials.

specializing in cardiovascular disease, well over a third of which was for consulting work. The total expenditures for that individual are slightly lower than the total received by the recipient with the highest expenditures in 2011 (approximately $143,000 to a neurologist) and FY11 (approximately $149,000 to a radiologist). Six out of the ten practitioners who were associated with the highest receipt of samples in 2012 were doctors specializing in internal medicine. Exhibits 9a and 9b.[5]

Products

The top fifty products by expenditure dollar totals (including clinical trials) were associated with between $43,000 and 1.2 million dollars each in expenditures in 2012, for a total of nearly 7 million dollars (roughly 69% of overall spending). Of those, 33 (66%) were pharmaceutical products, 6 (12%) were medical devices, and 11 (22%) were biologics. The top ten products by expenditure dollars for 2012 were all pharmaceutical, and accounted for approximately 4.1 million dollars in spending (including expenditures for clinical trials), or approximately 54% of overall spending. The top ten products by expenditure dollars for 2012, and their manufacturers and indications, were as follows:

Rank Product	Manufacturer	Product Type	Indication
1. Solanezumab	Eli Lilly	Pharmaceuticals	Alzheimer's Disease
2. Vytorin	Merck Sharpe & Dhome	Pharmaceuticals	Hyperlipidemia
3. Aprela	Pfizer	Pharmaceuticals	Rheumatoid Arthritis
4.Vanutide Cridificar	Pfizer	Pharmaceuticals	Alzheimer's Disease
5. Tudorza	Forest Laboratories	Pharmaceuticals	Chronic Obstructive Pulmonary Disease
6. Aubagio	Genzyme	Pharmaceuticals	Multiple Sclerosis
7. Ampyra	Acorda Therapeutics	Pharmaceuticals	Multiple Sclerosis
8. Bapineuzumab	Pfizer	Pharmaceuticals	Alzheimer's Disease
9. PIrfenidone	InterMune	Pharmaceuticals	Idiopathic Pulmonary Fibrosis
10. Alogliptin	Takeda Pharmaceuticals America	Pharmaceuticals	Type 2 Diabetes

Exhibits 2 and 10a.

[5] Vermont's Prescribed Product Gift Ban and Disclosure Law requires the Attorney General to include in his annual report "the amounts expended on the Green Mountain Care board." 18 V.S.A. § 4632(a)(5)(A). No expenditures were disclosed as having been received by any member of the board in 2012.

The top fifty products by sample distribution were associated with the distribution of between 390 and 4,300 samples each. Of those, 46 (92%) were pharmaceutical products and 4 (8%) were medical devices. No biologic products were sampled more than 390 times. The top ten products by sample totals for 2012 accounted for approximately 28,000 samples, or 39% of overall samples distributed in 2012. The top ten products by total number of samples distributed in 2012, and their manufacturers, product types and indications, were as follows:

Rank Product	Manufacturer	Product Type	Indication
1. Cymbalta	Eli Lilly	Pharmaceuticals	Depressive Disorder
2. Viibryd	Forest Laboratories	Pharmaceuticals	Depression
3. Advair	GlaxoSmithKline	Pharmaceuticals	Asthma
4. Abilify	Bristol-Myers Squibb	Pharmaceuticals	Schizophrenia
5. Bystolic	Forest Pharmaceuticals, (a subsidiary of Forest Laboratories)	Pharmaceuticals	Hypertension
6. Cialis	Eli Lilly	Pharmaceuticals	Erectile Dysfunction
7. Crestor	Astrazeneca	Pharmaceuticals	Hyperlipidemia
8. Nexium	Astrazeneca	Pharmaceuticals	Gastroesophageal Reflux Disease
9. Symbicort	Astrazeneca	Pharmaceuticals	Asthma
10. Namenda	Forest Laboratories	Pharmaceuticals	Alzheimer's Disease

Exhibits 2 and 10b.

Although no products are in both the top ten by expenditure dollars and samples, seven products were among the top 50 products by both expenditure dollars and samples: Daliresp, Januvia, Namenda, NovoLog, Viibryd, Vytorin and Zetia. Exhibits 10a and 10b.

Looking only at the 50 products with the greatest expenditures, including expenditures on clinical trials and research, the most prevalent indication was Alzheimer's, which was associated with more than 1.7 million dollars in expenditures. The second through fifth most prevalent indications were Hyperlipidemia (over 1 million dollars), Rheumatoid Arthritis (over $800,000), Diabetes (over $500,000) and Multiple Sclerosis (nearly $500,000). Of all five, only Alzheimer's Disease was not among the top five indications in both FY11 and 2011. Exhibit 11a.

Looking only at the 50 products with the greatest number of samples, the two most prevalent indications by a considerable margin were Depressive Disorder and Asthma, which were associated with over 7,000 samples each. Samples for products with the third through fifth most prevalent indications in 2012 were: Erectile Dysfunction (over 5,000 samples), Bipolar Disorder and/or Schizophrenia (over 4,500 samples) and Hyperlpidemia (over 4,200 samples). Exhibit 11b.

Seven indications were among the primary indications of both the top 50 products by expenditures and samples: Alzheimer's, Depression, Hyperlipidemia, Diabetes, Chronic

Obstructive Pulmonary Disease, Bipolar Disorder and/or Schizophrenia and Hypertension. Exhibits 11a and 11b.

Nature and Purpose of Expenditures

Approximately 85% of all expenditures in 2012 were in the form of cash or check to recipients, a proportion consistent with the 2011 and FY11 figures (81% and 85%, respectively). Approximately $800,000 dollars of 2012 expenditures took the form of educational materials; as a percentage of total expenditures (11%), this figure is roughly consistent with prior reporting periods (11% in FY10, 12 % in FY11 and 15% in 2011). In 2012, manufacturers loaned 179 medical devices to 28 recipients (consistent with the 170 medical devices to 32 recipients in 2011). Per Office guidance, no value is placed on the loan of medical devices. Exhibit 12.

Manufacturers reported that the purpose of roughly 3.7 million dollars (or 49%) of 2012 spending was for clinical trials. This is a marked increase from the 2011 totals (2.5 million dollars (or 33%)). Manufacturers also reported spending nearly 1.3 million dollars on research projects (17%), more than $800,000 on educational materials (11%), and more than $350,000 on consulting (5%). Exhibit 13.

Clinical Trial Expenditures

Manufacturers reported that the 3.7 million dollars spent on clinical trials were associated with 561 separate expenditures to 37 recipients. In addition, manufacturers disclosed that they funded 50 additional clinical trials in Vermont during the last half of 2011; under the delayed disclosure scheme laid out in the statute, manufacturers will disclose the details of those clinical trial expenditures at a future date.[6] Exhibits 13, 14a and 14b.

Samples

Of the approximately 73,000 samples distributed in 2012, more than 53,000 (73%) contained product, more than 17,000 (23%) contained vouchers or coupons for free or reduced price product, and nearly 8,000 (11%) contained other items, such as educational materials, non-prescribed items and cases/holders. Approximately 4,200 (6%) samples included two or more kinds of items (product, vouchers or other), while about 900 (1%) contained all three kinds of items. While overall distribution of samples was considerably lower in 2012 as compared to 2011 (over 73,000 in 2012 compared with nearly 106,000 in 2011), at least 28,000 of the 2011 samples were associated with prescription eyewear, a category of product that was largely exempt from reporting for the first time in 2012. Exhibit 15.

II. Description of Vermont's Prescribed Product Gift Ban and Disclosure Law

[6] Manufacturers also reported having spent an additional approximate amount of $443,000 on five clinical trials during calendar years 2007 through 2010; those expenditures were eligible for delayed disclosures for the reporting periods corresponding to those expenditure dates.

The Vermont Legislature enacted the Pharmaceutical Marketing Disclosure Law in 2002, and amended it in every year between 2004 and 2011 with the exception of 2008. In 2009, the legislature mandated reporting of expenditures for biologics and medical devices, as well as expenditures relating to clinical trials and research, both effective with the FY11 report. The legislature also mandated reporting of the distribution of samples effective with the 2011 report. The law is now known as the Prescribed Products Disclosure Law. Only minor amendments were made to the law in 2010 and 2011.

The law in effect for the activity described in this report required manufacturers of prescribed products to report to the Vermont Attorney General's Office "the value, nature, purpose, and recipient information" of allowable expenditures and permitted gifts and the "recipient, number of units, and dosage" of samples distributed to Vermont health care providers and institutions. 18 V.S.A. §§ 4632(a)(1), (2).

Many kinds of expenditures are banned in Vermont. In particular, the law bans manufacturers from giving gifts (including food), defined generally as "anything of value provided to a health care provider for free." 18 V.S.A. §§ 4631a(a)(5), (b)(1). Only the allowable expenditures and permitted gifts detailed as follows are exempt from this ban:

Allowable Expenditures:

- some payments associated with qualifying conferences or seminars
- some expenditures associated with qualifying clinical trials and research projects
- payment or reimbursement of reasonable expenses associated with technical training on medical devices
- royalties and licensing fees
- payments related to interviews for an employment opportunity or for health care services for employees
- other reasonable economic benefits provided at fair market value

18 V.S.A. § 4631a(a)(1).

Permitted Gifts:

- samples of prescribed products or reasonable amounts of some over-the-counter products for free distribution to patients
- short-term loans of medical devices
- reasonable quantities of medical device demonstration or evaluation units
- educational materials
- scholarships for medical students, residents and fellows to attend qualifying conferences or seminars
- rebates and discounts for prescribed products provided in the normal course of business

- FDA-approved drug labels
- free prescription or over-the-counter product or financial donations given to free clinics
- prescribed products distributed through manufacturer patient assistance programs
- some fellowship salary support payments
- coffee or other snacks or refreshments at a booth at a conference or seminar

18 V.S.A. § 4631a(b)(2).

The following allowable expenditures and permissible gifts were exempt from disclosure in 2012:

- royalties and licensing fees
- rebates and discounts for prescribed products
- certain payments relating to clinical trials
- interview of applicants or health care expenses of employees
- coffee or other snacks or refreshments at a booth at a conference or seminar
- certain loans of medical devices resulting in a purchase or lease of the device
- prescribed products distributed through patient assistance programs

18 V.S.A. §§ 4632(a)(1)(A), (a)(1)(B).

In 2009, the legislature eliminated the trade secret exemption which manufacturers had been permitted to claim in the past. However, disclosures of the distribution of samples as well as other product may only be reported to the public in aggregate form. 18 V.S.A. §§ 4632(a)(1)(B), (a)(1)(D), (a)(5). Thus, while expenditure disclosures have been posted along with this report on the Attorney General's Website: www.atg.state.vt.us, disclosures of the distribution of samples and other product have not.

III. Enforcement

Vermont's Prescribed Product Gift Ban and Disclosure Law requires the Attorney General to include in this annual report "[i]nformation on violations and enforcement actions" brought pursuant to the statute's enforcement provisions. 18 V.S.A. § 4632(a)(5)(B). During 2012, the Attorney General conducted dozens of investigations into potential violations of both the gift ban and the disclosure law. To date, the Attorney General has entered into 25 settlements resulting in payments to the state of $61,250.00; each of the 25 settlements resolved violations that were self-reported. Copies of the settlement documents can be found on the Attorney General's Website: www.atg.state.vt.us

Exhibit 1a: Expenditures and Samples by Manufacturer, 2012

Rank by Expenditure Total	Rank by Number of Samples	Manufacturer	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
1	3	Eli Lilly	$1,382,869.55	126	7,192	515
2	4	Pfizer	$1,186,787.15	209	6,183	617
3	64	Genentech	$439,087.40	22	6	11
4	**	Forest Laboratories	$362,728.00	98		12
5	6	Merck Sharpe & Dhome	$231,382.37	332	4,677	385
6	**	Genzyme	$206,511.00	27		4
7	22	sanofi-aventis US	$206,449.00	78	490	137
8	8	Takeda Pharmaceuticals America	$203,840.04	117	2,822	196
9	**	Acorda Therapeutics	$180,287.25	12		2
10	7	Abbott Laboratories	$168,392.88	1,443	3,593	351
11	10	Boehringer Ingelheim	$159,626.00	56	2,657	255
12	**	Masimo	$123,076.00	10		5
13	**	InterMune	$122,249.00	10		1
14	1	AstraZeneca	$121,988.00	95	8,670	549
15	**	Medtronic	$118,012.17	58		11
16	16	Novo Nordisk	$110,176.00	39	1,304	203
17	**	Baxter Healthcare	$107,413.80	7		2
18	2	GlaxoSmithKline	$103,293.68	42	8,021	526
19	**	McKesson Technologies	$91,937.00	3		3
20	**	The Medicines Company	$90,943.00	68		2
21	44	Amgen	$86,835.07	74	56	34
22	**	Vertex Pharmaceuticals	$80,790.15	3		3
23	**	Biosense Webster	$75,175.00	24		4
24	33	Amylin Pharmaceuticals	$74,874.00	46	194	56
25	78	Biogen Idec	$73,604.74	24	1	4
26	**	Ethicon Endo-Surgery	$64,497.00	51		36
27	21	Bayer HealthCare	$63,834.00	9	499	155
28	**	Merck	$63,665.87	54		16
29	**	Ethicon	$61,781.59	11		8
30	**	Zimmer	$57,223.00	20		12
31	26	Novartis	$54,456.00	41	411	72
32	14	Allergan	$49,512.94	28	1,493	96
33	**	St. Jude Medical	$49,108.09	19		4

Exhibit 1a: Expenditures and Samples by Manufacturer, 2012

Rank by Expenditure Total	Rank by Number of Samples	Manufacturer	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
34	**	Celgene	$45,227.53	13		3
35	9	Bristol-Myers Squibb	$44,740.00	31	2,819	306
36	47	UCB	$40,786.55	16	42	18
37	**	Globus Medical	$35,178.96	12		1
38	**	Incyte Corporaton	$34,464.28	11		4
39	**	Millennium Pharmaceuticals	$33,879.89	41		19
40	**	Merz Aesthetics	$33,118.01	39		7
41	**	GE Healthcare	$31,350.00	45		10
42	15	Astellas Pharma US	$30,961.02	54	1,459	216
43	**	Alcon Laboratories	$30,644.49	156		33
44	**	Covidien	$29,605.00	71		22
45	**	DePuy Mitek	$29,524.69	16		7
46	**	Synthes	$29,082.89	24		13
47	**	Vivus	$27,223.86	1		1
48	**	Smith & Nephew	$26,374.53	15		7
49	28	Purdue Pharma	$26,324.76	17	364	109
50	36	Eisai	$25,756.00	7	165	49
51	49	Medicis, a division of Valeant	$22,654.34	14	27	9
52	**	Olympus Corporation of the Americas	$22,287.00	2		2
53	**	CareFusion	$22,019.00	33		12
54	**	LifeCell	$20,192.00	5		2
55	**	Stryker	$20,116.72	91		51
56	**	Cook Medical	$17,443.30	25		12
57	**	Straumann Manufacturing	$16,768.00	126		126
58	**	Regeneron Pharmaceuticals	$14,238.42	13		6
59	**	Tactile Systems Technology	$13,933.77	6		1
60	**	ArthroCare	$12,934.62	11		4
61	**	Draeger Medical	$10,955.00	3		2
62	**	Codman & Shurtleff	$10,241.50	2		2
63	**	Thermo Fisher Scientific	$9,650.00	5		1
64	**	Lundbeck	$9,580.00	31		8
65	**	Merck/Organon USA	$9,167.84	104		51
66	**	Sanofi Pasteur	$8,911.00	13		3

Exhibit 1a: Expenditures and Samples by Manufacturer, 2012

Rank by Expenditure Total	Rank by Number of Samples	Manufacturer	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
67	**	Medivation	$8,799.00	1		1
68	**	Intuitive Surgical	$8,737.08	9		4
69	**	Actelion Pharmaceuticals US	$8,598.00	12		1
70	34	Warner Chilcott US	$8,171.00	1	173	55
71	**	Teva Pharmaceuticals	$8,094.44	19		3
72	**	DePuy Orthopaedics	$7,846.00	45		8
73	**	Valeritas	$7,523.53	11		4
74	**	W.L. Gore & Associates	$7,427.00	13		5
75	**	Seattle Genetics	$7,294.00	23		2
76	**	Maquet Cardiovascular	$7,228.00	9		1
77	**	Grifols Therapeutics	$6,860.34	2		2
78	**	Cadence Pharmaceuticals	$6,625.24	5		3
79	**	Edwards Lifesciences	$6,439.04	56		6
80	**	C.R. Bard	$6,067.54	3		3
81	12	Johnson & Johnson Vision Care	$6,040.00	5	2,153	61
82	**	ViiV Healthcare	$5,935.00	1		1
83	31	Watson Pharmaceuticals	$5,747.00	6	278	39
84	**	Ortho-Clinical Diagnostics	$5,373.63	15		10
85	43	Aptalis Pharma US	$5,300.00	4	59	16
86	68	Avanir Pharmaceuticals	$5,047.35	4	5	5
87	**	Oticon	$4,926.02	33		16
88	**	Theravance	$4,860.00	2		1
89	**	Biomet	$4,615.00	7		2
90	**	Advanced Bionics	$4,411.17	8		1
91	23	3M	$4,224.40	19	489	141
92	**	Cordis	$4,152.00	1		1
93	50	Roche Diagnostics Operations	$4,144.00	6	26	9
94	13	Shire	$4,028.22	7	1,530	44
95	**	SI-Bone	$3,975.42	7		3
96	**	Mentor Worldwide	$3,944.00	5		5
97	41	Ferring Pharmaceuticals	$3,933.57	20	64	28
98	17	Sunovion	$3,908.43	3	1,216	230
99	**	Syneron	$3,500.00	1		1

Exhibit 1a: Expenditures and Samples by Manufacturer, 2012

Rank by Expenditure Total	Rank by Number of Samples	Manufacturer	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
100	**	Arthrex	$3,449.87	8		4
101	**	Karl Storz Endoskope	$3,350.00	92		11
102	**	Coloplast	$3,195.02	2		2
103	**	Lantheus Medical Imaging	$3,185.33	1		1
104	**	United Therapeutics	$3,123.44	4		2
105	73	Hospira	$3,058.17	2	3	4
106	**	Vascular Solutions	$3,024.00	15		5
107	55	Ascend Therapeutics	$3,001.05	5	18	10
108	51	Gilead Sciences	$2,994.54	3	24	10
109	52	Cardinal Health	$2,816.97	38	22	16
110	25	LifeScan	$2,647.00	3	464	102
111	**	Integra LifeSciences	$2,633.43	7		3
112	**	Hill-Rom	$2,502.00	3		3
113	**	KCI USA	$2,480.00	2		2
114	**	LEO Pharma	$1,901.00	8		1
115	**	Dendreon	$1,750.00	4		1
116	**	Cangene BioPharma	$1,727.66	3		1
117	74	3M ESPE Dental Products	$1,625.00	1	3	4
118	39	Becton Dickinson	$1,378.09	2	77	15
119	**	MAKO Surgical	$1,336.00	4		1
120	54	B. Braun Medical	$1,310.80	2	19	8
121	11	Daiichi Sankyo	$1,175.28	7	2,308	110
122	**	Optimer Pharmaceuticals	$1,150.00	2		1
123	**	Biomet 3i	$1,133.91	11		7
124	**	Alexion Pharmaceuticals	$1,125.00	2		2
125	**	DePuy Synthes Spine	$1,000.00	1		1
126	**	Insulet Corporation	$970.00	19		12
127	79	Fisher & Paykel Healthcare	$939.00	1	1	2
128	27	Medline Industries	$875.40	3	407	43
129	**	Jazz Pharmaceuticals	$805.03	1		1
130	35	Reckitt Benckiser Pharmaceuticals	$642.00	2	172	74
131	**	Mylan Pharmaceuticals	$612.01	3		2
132	**	Surgi-Care	$600.00	2		1

Exhibit 1a: Expenditures and Samples by Manufacturer, 2012

Rank by Expenditure Total	Rank by Number of Samples	Manufacturer	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
133	**	Jazz Pharmaceuticals Commercial Corporation (Formerly Azur Pharma)	$583.99	1		1
134	**	Siemens Hearing Instruments	$535.58	8		4
135	**	Given Imaging	$500.00	1		1
136	**	Terumo Medical Corporation	$360.00	1		1
137	32	Valeant Pharmaceuticals North America	$342.00	18	203	40
138	**	EUSA Pharma USA	$327.81	3		2
139	**	MedImmune	$300.71	6		6
140	**	Savient Pharmaceuticals	$273.00	32		9
141	**	Vidara Therapeutics	$200.78	6		1
142	**	Dexcom	$179.25	1		1
143	80	ConvaTec	$171.33	1	1	2
144	63	Sigma-Tau Pharmaceuticals	$148.69	1	7	8
145	**	Spine Wave	$132.22	3		2
146	24	Otsuka America Pharmaceuticals	$95.00	1	471	48
147	**	Iroko Pharmaceuticals	$90.49	1		1
148	**	QLT Ophthalmics	$85.30	1		1
149	**	Mallinckrodt	$79.76	3		3
150	**	Aspen Surgical	$47.00	1		1
151	**	Biomet Microfixation	$40.20	4		1
152	**	Animas	$27.00	1		1
153	62	Depomed	$26.30	16	7	13
154	30	Galderma Laboratories	$17.50	9	318	17
155	**	EBI dba Biomet Spine and Bone Healing Technologies	$16.00	1		1
156	**	NuVasive	$11.62	2		2
157	69	Ormco	$10.00	1	5	3
158	72	B. Braun Interventional Systems	$9.00	1	4	1
*	5	Forest Pharmaceuticals (subsidiary of Forest Laboratories)			5,798	397
*	18	Janssen Pharmaceuticals			966	145
*	19	Bausch & Lomb			777	61
*	20	Kowa Pharmaceuticals America			545	151

Exhibit 1a: Expenditures and Samples by Manufacturer, 2012

Rank by Expenditure Total	Rank by Number of Samples	Manufacturer	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
*	29	Endo Pharmaceuticals			361	100
*	37	Salix Pharmaceuticals			140	20
*	38	MSD Oss B.V. (subsidiary of Merck)			94	50
*	40	Auxilium Pharmaceuticals			74	30
*	42	Actavis			61	61
*	45	Metrex			50	35
*	46	Nestle HealthCare Nutrition			49	17
*	48	Zogenix			34	20
*	53	Actient Pharmaceuticals			20	9
*	56	ISTA Pharmaceuticals			18	4
*	57	Meda Pharmaceuticals			17	9
*	58	Mylan Specialty			15	12
*	59	Moore Medical			10	3
*	60	Kerr Corporation			8	4
*	61	McKesson Medical-Surgical Minnesota Supply			8	4
*	65	Arbor Pharmaceuticals			6	5
*	66	Cochlear Americas			6	1
*	67	Janssen Therapeutics			6	6
*	70	Janssen Biotech			5	3
*	71	Ossur Americas Inc			5	2
*	75	Inspire Pharmaceuticals			3	3
*	76	Merit Medical Systems			3	2
*	77	Fresenius Medical Care North America			2	1
*	81	Dr. Reddy's Laboratories			1	1
*	82	Shionogi			1	1
Totals:		**187 Manufacturers**	**$7,629,644.67**	**5,059**	**72,755**	

*Manufacturer did not disclose any expenditures.

**Manufacuturer did not dislcose any samples.

Exhibit 1b: Expenditures and Samples by Manufacturer Detail - Top 10 Manufacturers by Number of Samples, 2012

Rank by Expenditure Total	Rank by Number of Samples	Manufacturer	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
14	1	AstraZeneca	$121,988.00	95	8,670	549
18	2	GlaxoSmithKline	$103,293.68	42	8,021	526
1	3	Eli Lilly	$1,382,869.55	126	7,192	515
2	4	Pfizer	$1,186,787.15	209	6,183	617
*	5	Forest Pharmaceuticals (subsidiary of Forest Laboratories, Inc.)	$0.00		5,798	397
5	6	Merck Sharpe & Dhome	$231,382.37	332	4,677	385
10	7	Abbott Laboratories	$168,392.88	1,443	3,593	351
8	8	Takeda Pharmaceuticals America	$203,840.04	117	2,822	196
35	9	Bristol-Myers Squibb	$44,740.00	31	2,819	306
11	10	Boehringer Ingelheim	$159,626.00	56	2,657	255
Totals:			**$3,602,919.67**	**2,451**	**52,432**	

*Manufacturer did not dosclose any expenditures.

Exhibit 2: Expenditures and Samples by Product Type, 2012

Product Type	Expenditure Total	Percent of Expenditure Total	Number of Expenditures	Percent of Number of Expenditures	Number of Samples	Percent of Number of Samples
Pharmaceutical	$6,807,747.76	67.0%	2802	34.3%	79,048	87.3%
Medical Device	$1,870,517.79	18.4%	4852	59.4%	10,054	11.1%
Biologic	$1,423,539.66	14.0%	372	4.6%	126	0.1%
Unknown	$31,500.00	0.3%	2	0.0%	0	0.0%
Other/Other OTC/Unknown	$24,514.45	0.2%	142	1.7%	876	1.0%
Combination Product	$4,638.50	0.1%	5	0.1%	331	0.4%
Medical Food	$0.00	0.0%	0	0.0%	73	0.1%
Medical Equipment/Supplies	$0.00	0.0%	0	0.0%	25	0.0%
Totals:	**$10,162,458.16**		**8,175**		**90,533**	

Note: This exhibit is meant to show only the proportional breakdown of expenditures and samples by product type. For purposes of this exhibit, when manufacturers disclosed an expenditure in connection with several different products, or a sample containing several products, the Attorney General's Office assigned the expenditure or sample to each of the products disclosed in connection with the expenditure or sample.

Exhibit 3: Total Expenditures, FY04-2012



Total Expenditures	
FY04	$4,026,576.24
FY05	$2,196,592.26
FY06	$2,367,604.33
FY07	$3,139,584.63
FY08	$2,943,321.38
FY09	$2,599,589.00
FY10 Pharmaceutical Expenditures, Excluding Clinical Trials and Research	$1,835,101.79
FY10 Pharmaceutical Expenditures	$3,973,654.69
FY10 Biologic and Medical Device Expenditures	$855,914.49
FY10 Total Expenditures	$4,829,569.18
FY11 Pharmaceutical Expenditures, Excluding Clinical Trials and Research	$2,183,451.56
FY11 Pharmaceutical Expenditures	$3,952,608.42
FY11 Biologic and Medical Device Expenditures	$1,672,282.65
FY11 Total Expenditures	$5,624,891.07
2011 Pharmaceutical Expenditures, Excluding Clinical Trials and Research	$2,980,770.44
2011 Pharmaceutical Expenditures	$5,111,507.63
2011 Biologic and Medical Device Expenditures	$2,142,179.29
2011 Other Expenditures	$249,504.77
2011 Total Expenditures	$7,503,191.70
2012 Pharmaceutical Expenditures, Excluding Clinical Trials and Research	$1,201,726.21
2012 Pharmaceutical Expenditures	$5,357,720.50
2012 Biologic and Medical Device Expenditures	$2,235,785.67
2012 Other Expenditures	$36,138.50
2012 Total Expenditures	$7,629,644.67

Exhibit 4: Total Manufacturers Reporting Expenditures and Samples, FY04-2012



Total Number of Manufacturers Reporting Expenditures	
FY04	55
FY05	72
FY06	83
FY07	86
FY08	78
FY09	85
FY10 Pharmaceutical Expenditures	58
FY10 Total Expenditures	141
FY11 Pharmaceutical Expenditures	64
FY11 Total Expenditures	154
2011 Pharmaceutical Expenditures	77
2011 Total Expenditures	181
2011 Grand Total Expenditures and Samples	211
2012 Pharmaceutical Expenditures	75
2012 Total Expenditures	158
2012 Grand Total Expenditures and Samples	187

Note: For purposes of this exhibit, when manufacturers disclosed one expenditure as associated with several different products, the Attorney General's Office assigned the entire expenditure to the first product associated with the expenditure.

Exhibit 5:Total Number of Expenditures and Samples with Expenditure Detail, FY04-2012





Total Number of Expenditures	
FY04	13,088
FY05	13,086
FY06	15,043
FY07	15,505
FY08	15,880
FY09	14,636
FY10 Pharmaceutical Expenditures	2,322
FY10 Total Expenditures	3,122
FY11 Pharmaceutical Expenditures	2,107
FY11 Total Expenditures	4,277
2011 Pharmaceutical Expenditures	2,082
Medical Device Expenditures	3,050
2011 Other Expenditures	1,047
2011Total Expenditures	6,179
2011 Grand Total Expenditures and Samples	112,017
2012 Pharmaceutical Expenditures	2,203
Medical Device Expenditures	2,849
2012 Other Expenditures	7
2012Total Expenditures	5,059
2012 Grand Total Expenditures and Samples	77,814

*Other expenditures refers to expenditures associated with combination and unknown products.

Note: For purposes of this exhibit, whne manufacturers disclosed one expenditure as associated with different products, the Attorney General's
assigned the entire expenditure to the forst product associated with the expenditure.

Exhibit 6a: Top Five Manufacturers - Manufacturers with Highest Expenditures, FY07-2012

2012 Rank by Expenditure Total (Rank by Number of Samples)	FY07	FY08	FY09	FY10	FY11	2011	2012
1(3)	Eli Lilly	Eli Lilly	Eli Lilly	Pfizer	Abbott Laboratories	Aptalis	Eli Lilly
2(4)	Pfizer	Pfizer	Pfizer	GlaxoSmithKline	Novartis Pharmaceuticals	Pfizer	Pfizer
3(64)	UCB	Novartis Pharmaceuticals	Forest Pharmaceuticals	Novartis Pharmaceuticals	GlaxoSmithKline	Novartis Pharmaceuticals	Genentech
4(n/a)	Novartis Pharmaceuticals	Merck	Merck and Merck Schering Plough	Daiichi Sankyo	Eli Lilly	Abbott Laboratories	Forest Laboratories
5(6)	Merck	Forest Pharmaceuticals	GlaxoSmithKline	Eli Lilly	Medtronic	Medtronic	Merck Sharpe & Dhome
Expenditure Total for Top 5 Manufacturers	$1,756,150.56	$1,519,745.18	$1,230,540.64	$2,266,455.09	$2,164,273.99	$3,343,504.24	$3,602,854.47
Percentage of Overall Expenditure Total Attributable to Expenditures of Top 5 Manufacturers*	56%	52%	47%	47%	39%	45%	47%

* Approximately 18% of the overall sample total was attributable to the samples of the top five manufacturers by expenditure total.

Exhibit 6b: Top Five Manufacturers - Manufacturers With Most Samples, 2011-2012

2012 Rank by Number of Samples (Rank by Expenditure Total)	2011	2012
1(14)	CIBA Vision	AstraZeneca
2(18)	Cooper Vision	GlaxoSmithKline
3(1)	GlaxoSmithKline	Eli Lilly
4(2)	Pfizer	Pfizer
5 (n/a)	Vistakon	Forest Pharmaceuticals (subsidiary of Forest Laboratories)
Number of Samples for Top 5 Manufacturers	47,052	35,864
Percentage of Overall Sample Total Attributable to Top 5 Manufacturers*	44%	49%

*Approximately 37% of the overall expenditure total was attributable to the expenditures of the top five manufacurers by number of samples.

Exhibit 7: Expenditures and Samples by Recipient Type, 2012

Recipient Type	Expenditure Total	Number of Expenditures	Number of Samples	Number of Recipients
Clinical Trial/Research	$5,004,210.25	596	0	41
Doctor	$854,211.25	1,640	55,675	1,596
Aggregate*	$819,131.23	1,658	0	n/a
Hospital/Clinic	$358,029.42	325	776	40
Academic Institution	$329,604.25	110	25	1
Professional/Educational/Patient Organization	$127,442.78	69	4	33
Other Health Care Provider	$90,697.13	441	6,706	480
Pharmacist/Pharmacy/Pharmacy Technician	$32,788.58	32	3,000	155
Other Prescriber	$9,949.64	158	6,316	258
Other	$2,796.78	18	3	5
Nursing Home/Continuous Care Facility	$613.36	2	85	21
Unknown Health Care Provider	$170.00	10	119	39
Other - Optical	n/a	0	46	12
Totals:	**$7,629,644.67**	**5,059**	**72,755**	

*The Attorney General's Office allows manufacturers to report permitted gifts with a fair market value below $25 as having gone to all Vermont health care providers and institutions in the aggregate. The overwhelming majority of aggregate spending is related to educational materials.

Exhibit 8a: Expendiures by Specialty or Credential for Individual Health Care Providers who Received $3,000 or More in Expenditures, FY08-2012

2012 Rank	Specialty or Credential	FY08 Expenditure Total	FY09 Expenditure Total	FY10 Expenditure Total	FY11 Expenditure Total	2011 Expenditure Total	2012 Expenditure Total
1	Cardiovascular Disease	$47,034.11	$49,516.79	$24,499.00	$12,082.00	$86,292.33	$125,964.14
2	Orthopaedic Surgery			$4,106.00	$75,607.74	$132,384.24	$116,381.45
3	Internal Medicine	$272,737.14	$206,178.83	$29,029.49	$104,570.25	$146,077.64	$113,984.49
4	Emergency Medicine						$75,712.00
5	Unknown						$73,823.00
6	Endocrinology, Diabetes and Metabolism	$176,347.61	$86,345.52	$40,083.21	$36,676.00	$39,891.62	$41,958.24
7	Advanced Practice Registered Nurse (APRN)	$80,865.25	$80,384.07	$31,990.58	$43,339.83	$78,387.33	$40,841.62
8	Geriatric Medicine	$51,672.20	$77,338.32	$68,987.88	$108,524.57	$16,408.96	$31,927.61
9	Neurology	$193,377.79	$159,364.01	$141,546.85	$184,940.17	$186,353.49	$29,156.74
10	Cardiac Electrophysiology					$150,698.27	$28,763.00
11	Urology	$17,614.24	$18,233.21	$8,859.34	$3,098.43	$3,031.07	$27,680.08
12	Obstetrics and Gynecology				$4,300.00	$12,859.52	$21,113.00
13	Ophthalmology			$11,750.00	$3,351.87		$18,676.73
14	Osteopathic Physician	$78,645.84	$60,461.04	$64,349.16	$31,561.29	$11,581.32	$16,668.00
15	Addiction Psychiatry		$9,558.69			$26,100.79	$16,009.72
16	Dermatology	$15,190.14	$6,449.30	$3,220.00	$3,776.40	$10,398.12	$15,516.00
17	Psychiatry	$396,978.52	$378,729.91	$151,001.77	$125,142.44	$46,959.53	$13,606.43
18	Doctor: No Specialty Listed				$59,658.54		$12,838.01
19	Clinical Neurophysiology	$7,246.02				$7,062.92	$8,849.00
20	General Vascular Surgery					$25,629.37	$8,741.50
21	Infectious Disease						$8,500.00
22	Cardiovascular Surgery					$45,404.52	$8,372.00
23	Registered Nurse (RN)	$23,981.28	$34,948.61	$20,773.74	$13,689.66		$8,025.00
24	Hematology		$16,777.16	$19,088.85	$17,251.00	$51,150.54	$7,595.37

Exhibit 8a: Expendiures by Specialty or Credential for Individual Health Care Providers who Received $3,000 or More in Expenditures, FY08-2012

2012 Rank	Specialty or Credential	FY08 Expenditure Total	FY09 Expenditure Total	FY10 Expenditure Total	FY11 Expenditure Total	2011 Expenditure Total	2012 Expenditure Total
25	Limited Temporary Permit Physician	$7,508.19	$33,148.00			$5,736.00	$7,048.62
26	Clinical Pharmacology						$4,860.00
27	Psychologist - Doctorate						$4,432.50
28	Audiologist						$4,411.17
29	Gastroenterology	$5,209.76		$14,966.00		$4,749.54	$4,060.00
30	Critical Care Medicine	$6,338.00	$6,467.59	$12,085.00	$9,872.00	$38,378.24	$3,838.27
31	Surgery				$3,557.00		$3,684.34
32	Pain Management					$50,790.96	$3,503.75
*	Allergy and Immunology	$38,567.50	$4,600.38			$10,872.64	
*	Anesthesiology				$6,469.95	$11,087.82	
*	Blood Banking/Transfustion Medicine					$12,235.34	
*	Dentist				$5,038.00		
*	Diagnostic Radiology				$17,763.44	$89,375.28	
*	Family Practice	$96,115.95	$122,691.13			$8,498.82	
*	Geriatric Psychiatry	$89,369.64	$15,710.52				
*	Ionizing Radiation Privileges	$120,879.10	$104,694.16	$16,052.01	$207,617.77		
*	Licensed Practical Nurse (LPN)					$18,302.14	
*	Medical Oncology	$34,852.85	$52,040.04	$53,443.91	$61,354.96		
*	Nephrology	$11,361.87		$18,750.00	$7,790.04		
*	Pediatric Gastroenterology			$8,549.46		$5,257.02	
*	Pediatrics	$35,771.53	$72,459.58	$30,304.44			
*	Physical Medicine and Rehabilitation	$12,501.48	$17,775.75	$6,758.08	$7,871.44		
*	Physician Assistant (PA)	$18,915.32	$3,880.65			$4,000.00	
*	Pulmonary Disease	$6,858.42	$3,868.91	$3,476.57	$4,596.19		
*	Radiology				$149,416.09		

Exhibit 8a: Expendiures by Specialty or Credential for Individual Health Care Providers who Received $3,000 or More in Expenditures, FY08-2012

2012 Rank	Specialty or Credential	FY08 Expenditure Total	FY09 Expenditure Total	FY10 Expenditure Total	FY11 Expenditure Total	2011 Expenditure Total	2012 Expenditure Total
*	Thoracic Surgery			$6,350.58	$37,335.73		
	Total Expenditures:	**$1,741,093.22**	**$1,621,622.17**	**$758,031.34**	**$1,346,252.81**	**$1,335,955.36**	**$906,541.78**
	Total Recipients:	**104**	**102**	**44**	**56**	**65**	**60**

*There were no doctors with these specialties, or other individual health care providers with these credentials who received $3,000 or more in 2012.

Note: For purposes of this exhibit, expenditures assiciated with clinical trials have been excluded. Doctor specialties are self-reported; other health care provider credentials are according to licensure.

Exhibit 8b: Samples by Specialty or Credential for Individual Health Care Providers who Received 250 or More Samples, 2011-2012

2012 Rank	Specialty or Credential	Number of Samples 2011	Number of Samples 2012
1	Internal Medicine	7,423	8363
2	Family Practice	6,136	6086
3	Physician Assistant (PA)	2,011	2597
4	Critical Care Medicine	1,185	1158
5	Cardiovascular Disease	638	809
6	Advanced Practice Registered Nurse (APRN)	279	626
7	Endocrinology, Diabetes and Metabolism	836	404
8	Optometrist	21,831	359
9	Psychiatry		275
10	Pediatrics		270
11	Allergy and Immunology		255
	Total Number of Samples:	**40,339**	**21,202**
	Total Recipients:	**52**	**43**

Note: Doctor Specialties are self-reported; other health care provider credentials are according to licensure.

Exhibit 9a: Expenditures by Payment Purpose for Individual Health Care Providers Receiving $3,000 or More in Expenditures, 2012

Rank	Healthcare Provider Specialty or Credential	Expenditure Total	Conference Sponsorship	Consulting/Surveys	Educational Materials	Faculty Expense	Faculty Honoraria/ Speaker Fee	Medical Device - Loans, Demos	Medical Device Training - Other Expenses	Other	Other Fair Market Value Payment	Research Project - Expenses	Research Project - Gross Compensation
1	Cardiovascular Disease	$125,964.14		$47,483.00	$121.14	$150.00	$6,000.00			$289.00	$57,119.00	$12,302.00	$2,500.00
2	Orthopaedic Surgery	$116,381.45		$76,692.41	$157.06	$6,890.35	$20,625.00	$4,933.33	$1,194.17	$5,889.13			
3	Internal Medicine	$113,984.49		$23,231.52		$26,934.12	$31,350.00	$3,164.00		$267.85			$29,037.00
4	Emergency Medicine	$75,712.00		$75,712.00									
5	Unknown	$73,823.00		$1,073.00			$72,750.00						
6	Endocrinology Diabetes and Metabolism	$41,958.24		$7,356.17		$11,265.23	$23,200.00	$136.84					
7	Advanced Practice Registered Nurse (APRN)	$40,841.62		$5,266.33	$73.00	$1,792.04	$13,750.00			$3,583.78	$16,376.47		
8	Geriatric Medicine	$31,927.61		$27,618.89		$508.72	$3,800.00						
9	Neurology	$29,156.74		$11,951.36		$925.38	$16,280.00						
10	Cardiac Electrophysiology	$28,763.00		$23,138.00			$5,625.00						
11	Urology	$27,680.08			$206.95		$17,750.00				$9,723.13		
12	Obstetrics and Gynecology	$21,113.00			$44.00		$3,000.00	$15,069.00			$3,000.00		
13	Ophthalmology	$18,676.73			$256.73			$18,378.00		$42.00			
14	Osteopathic Physician	$16,668.00									$16,668.00		
15	Addiction Psychiatry	$16,009.72		$9,329.16		$2,180.56	$4,500.00						
16	Dermatology	$15,516.00						$15,444.00		$72.00			
17	Psychiatry	$13,606.43		$3,908.43		$936.00	$3,000.00				$5,762.00		
18	Doctor: No Specialty Listed	$12,838.01						$12,838.01					

Exhibit 9a: Expenditures by Payment Purpose for Individual Health Care Providers Receiving $3,000 or More in Expenditures, 2012

Rank	Healthcare Provider Specialty or Credential	Expenditure Total	Conference Sponsorship	Consulting/Surveys	Educational Materials	Faculty Expense	Faculty Honoraria/ Speaker Fee	Medical Device - Loans, Demos	Medical Device Training - Other Expenses	Other	Other Fair Market Value Payment	Research Project - Expenses	Research Project - Gross Compensation
19	Clinical Neurophysiology	$8,849.00				$1,616.00	$6,500.00			$733.00			
20	General Vascular Surgery	$8,741.50		$8,741.50									
21	Infectious Disease	$8,500.00		$8,500.00									
22	Cardiovascular Surgery	$8,372.00				$3,228.00	$4,000.00	$1,144.00					
23	Registered Nurse (RN)	$8,025.00	$5,000.00			$400.00	$2,100.00				$525.00		
24	Hematology	$7,595.37			$75.00					$118.63	$7,401.74		
25	Limited Temporary Permit Physician	$7,048.62			$1,735.62				$5,313.00				
26	Clinical Pharmacology	$4,860.00		$4,860.00									
27	Psychologist - Doctorate	$4,432.50		$4,432.50									
28	Audiologist	$4,411.17			$82.80			$4,328.37					
29	Gastroenterology	$4,060.00											$4,060.00
30	Critical Care Medicine	$3,838.27		$3,838.27									
31	Surgery	$3,684.34							$3,684.34				
32	Pain Management	$3,503.75			$3.75		$3,500.00						
	Totals:	**$906,541.78**	**$5,000.00**	**$343,132.54**	**$2,756.05**	**$56,826.39**	**$237,730.00**	**$75,435.55**	**$10,191.51**	**$10,995.39**	**$116,575.34**	**$12,302.00**	**$35,597.00**

Note: For purposes of this exhibit, expenditures associated with clinical trials have been excluded. Doctor specialties are self-reported; other health care provider credential are according to licensure.

Exhibit 9b: Sample Content Detail for Individual Health Care Providers Receiving 250 or More Samples, 2012

Rank	Specialty or Credential	Total Number of Samples	Contents of Sample by Content Category			Contents of Sample by Product Type*			
			Product	Voucher	Other	Combination Product	Medical Devices	Other/Other OTC/Unknown	Pharmaceuticals
1	Internal Medicine	1,492	1,401	111	58	6	74	7	1,665
2	Internal Medicine	1,269	1,160	133	50	5	49	7	1,452
3	Family Practice	1,054	957	120	39				1,131
4	Physician Assistant (PA)	971	852	143	18	4	10		1,091
5	Internal Medicine	880	789	102	25	22	22		965
6	Internal Medicine	826	721	122	32	9			980
7	Internal Medicine	712	620	98	23		19	7	826
8	Physician Assistant (PA)	698	648	61	21	6			793
9	Internal Medicine	685	617	84	32		27		768
10	Family Practice	635	551	93	13	8	13		711
11	Critical Care Medicine	560	500	79	5	4			606
12	Family Practice	557	490	75	44	8	87		624
13	Internal Medicine	519	451	81	23	10	42		614
14	Cardiovascular Disease	509	493	38	12				551
15	Internal Medicine	465	402	63	12	6	27		502
16	Family Practice	460	352	96	44	2	61		511
17	Family Practice	447	400	48	18	3			510
18	Internal Medicine	434	354	74	31	4	55		466
19	Endocrinology Diabetes and Metabolism	404	370	47	14	12	52		450
20	Family Practice	372	294	75	32		10	7	456
21	Internal Medicine	371	323	49	12	11	63		387
22	Family Practice	362	256	108	29	4	84	8	372
23	Family Practice	362	294	71	23	2	19		400
24	Internal Medicine	362	305	58	9				394
25	Optometrist	359	359				273	62	24
26	Family Practice	351	296	64	18		34		411
27	Internal Medicine	348	243	97	21	3			411
28	Physician Assistant (PA)	342	305	42	9				432
29	Advanced Practice Registered Nurse (APRN)	325	293	40	27	2	93		363

Exhibit 9b: Sample Content Detail for Individual Health Care Providers Receiving 250 or More Samples, 2012

Rank	Specialty or Credential	Total Number of Samples	Contents of Sample by Content Category			Contents of Sample by Product Type*			
			Product	Voucher	Other	Combination Product	Medical Devices	Other/Other OTC/Unknown	Pharmaceuticals
30	Family Practice	325	300	25	12				366
31	Critical Care Medicine	315	254	57	9	3	21		330
32	Advanced Practice Registered Nurse (APRN)	301	208	43	94				412
33	Family Practice	300	218	74	20		54		337
34	Cardiovascular Disease	300	276	42	13				351
35	Physician Assistant (PA)	296	265	31	3	3			321
36	Family Practice	296	239	60	9	4	13		313
37	Family Practice	292	257	40	4			7	322
38	Physician Assistant (PA)	290	260	33	6				332
39	Critical Care Medicine	283	254	30					285
40	Psychiatry	275	130	37	117				296
41	Family Practice	273	212	64	14	1	29		290
42	Pediatrics	270	116	54	100			28	243
43	Allergy and Immunology	255	232	23					256
	Totals:	**21,202**	**18,317**	**2,885**	**1,095**	**142**	**1,231**	**133**	**23,320**

*No biologic products were included in any sample distributed to individual health care providers receving 250 or more samples in 2012.

Note: Doctor specialties are self-reported; other health care provider credentials are according to licensure.

Exhibit 10a: Top Products - 50 Products with Greatest Expenditures, 2012

Rank	Product Name	Manufacturer	Product Type	Primary Indication	Expenditure Total	Number of Times Sampled
1	Solanezumab	Eli Lilly	Pharmaceuticals	Alzheimer's Disease	$1,128,818.00	**
2	Vytorin*	Merck Sharpe & Dhome	Pharmaceuticals	Hyperlipidemia	$988,409.00	522
3	Aprela	Pfizer	Pharmaceuticals	Rheumatoid Arthritis	$700,000.00	**
4	Vanutide Cridificar	Pfizer	Pharmaceuticals	Alzheimer's Disease	$296,218.76	**
5	Tudorza	Forest Laboratories	Pharmaceuticals	Chronic Obstructive Pulmonary Disease	$256,562.00	142
6	Aubagio	Genzyme	Pharmaceuticals	Multiple Sclerosis	$204,348.00	**
7	Ampyra	Acorda Therapeutics	Pharmaceuticals	Multiple Sclerosis	$180,287.25	**
8	Bapineuzumab	Pfizer	Pharmaceuticals	Alzheimer's Disease	$134,748.10	**
9	PIrfenidone	InterMune	Pharmaceuticals	Idiopathic Pulmonary Fibrosis	$122,249.00	**
10	Alogliptin	Takeda Pharmaceuticals America	Pharmaceuticals	Type 2 Diabetes	$117,105.89	**
11	Ranibizumab	Genentech	biologics	Neovascular (Wet) Age-Related Macular Degeneration	$112,259.00	**
12	Victoza	Novo Nordisk	Pharmaceuticals	Type 2 Diabetes	$108,928.00	257
13	Rad-57	Masimo	Medical Devices	Noninvasive Patient Monitoring	$103,568.00	**
14	Emend	Merck Sharpe & Dhome	Pharmaceuticals	Nausea and Vomiting	$103,433.20	6
15	Coronary Stent	Medtronic	Medical Devices	Coronary Disease	$103,046.84	**
16	Januvia*	Merck Sharpe & Dhome	Pharmaceuticals	Type 2 Diabetes	$102,663.58	604
17	Unknown Product: Biologics	Genentech	biologics	Unknown	$99,505.20	**
18	Actemra	Genentech	biologics	Rheumatoid Arthritis	$92,690.83	**
19	Horizon	McKesson Technologies	Medical Devices	Vision Correction	$91,937.00	**
20	Alimta	Eli Lilly	Pharmaceuticals	Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer	$91,685.00	**
21	Angiomax	The Medicines Company	Pharmaceuticals	Angina	$90,943.00	**
22	Daliresp*	Forest Laboratories	Pharmaceuticals	Chronic Obstructive Pulmonary Disease	$88,932.00	752
23	Tocilizumab	Genentech	biologics	Rheumatoid Arthritis	$80,032.71	**
24	B-Domainless Factor VIII	Baxter Healthcare	Biologics	Hemophilia A	$79,964.80	**
25	Pegasys	Genentech	Biologics	Hepatitis C	$79,778.73	2
26	Rituxan	Genentech	Biologics	Non-Hodgkin's Lymphoma	$77,778.73	**
27	Byetta	Amylin Pharmaceuticals	Pharmaceuticals	Type 2 Diabetes	$74,773.00	83
28	LY451395	Eli Lilly	Pharmaceuticals	Alzheimer's Disease	$71,245.30	**
29	Ablation Catheters/Accessories	Biosense Webster	Medical Devices	Atrial Flutter	$67,997.00	**
30	Incivek	Vertex Pharmaceuticals	Pharmaceuticals	Hepatitis C	$65,790.15	**

Exhibit 10a: Top Products - 50 Products with Greatest Expenditures, 2012

Rank	Product Name	Manufacturer	Product Type	Primary Indication	Expenditure Total	Number of Times Sampled
31	NovoLog*	Novo Nordisk	Pharmaceuticals	Type 2 Diabetes	$62,414.00	513
32	Avonex	Biogen Idec	biologics	Multiple Sclerosis	$61,640.74	1
33	Levemir	Novo Nordisk	Pharmaceuticals	Type 2 Diabetes	$61,422.00	364
34	Namenda*	Forest Laboratories	Pharmaceuticals	Alzheimer's Disease	$59,241.00	1545
35	Neulasta	Amgen	biologics	Febrile Neutropenia	$57,726.02	1
36	SAR110894D	Sanofi-aventis U.S.	Pharmaceuticals	Alzheimer's Disease	$57,140.00	**
37	Zaltrap	Sanofi-aventis U.S.	biologics	Metastatic Colorectal Cancer	$54,988.00	**
39	Symbyax	Eli Lilly	Pharmaceuticals	Bipolar I Disorder	$54,836.26	**
38	Prozac	Eli Lilly	Pharmaceuticals	Depressive Disorder	$54,836.26	**
40	Viibryd*	Forest Laboratories	Pharmaceuticals	Depressive Disorder	$54,441.00	3500
41	Betaseron	Bayer HealthCare	Pharmaceuticals	Multiple Sclerosis	$52,857.00	264
42	Kogenate	Bayer HealthCare	Pharmaceuticals	Hemophilia A	$52,848.00	**
43	Edarbi	Takeda Pharmaceuticals America	Pharmaceuticals	Hypertension	$52,594.66	91
44	Brilinta	AstraZeneca	Pharmaceuticals	Acute Coronary Syndrome	$51,341.00	130
45	Mirena	Bayer HealthCare	Pharmaceuticals	Contraception	$49,469.00	**
46	Aranesp	Amgen	Biologics	Chronic Kidney Disease	$48,179.67	**
47	Suture	Ethicon	Medical Devices	Suture	$48,050.00	**
48	Zetia*	Merck Sharpe & Dhome	Pharmaceuticals	Hyperlipidemia	$47,253.23	426
49	Nintedanib	Boehringer Ingelheim	Pharmaceuticals	Anti-vascular anti-cancer agent	$47,101.00	**
50	Development Project 1:51 - polyaxial head - deformity pedicle screw	Zimmer	Medical Devices	Disc Disease	$43,718.00	**
	Totals:				**$6,987,794.92**	**9203**

* This product was also among the 50 products associated with the greatest frequency of sampling (see Exhibit 10b).

** No samples were reported as having been associated with this product.

Note: For purposes of this exhibit, when manufactureres disclosed an expenditure in connection with several different products, or a sample containing several products, the Attorney General's Office assigned the expenditure or sample to each of the products disclosed in connection with the expenditure or sample. Where applicable, primary indication is as according to the FDA.

Exhibit 10b: Top Products - 50 Products with Greatest Number of Samples, 2012

Rank	Product Name	Manufacturer	Product Type	Primary Indication	Number of Times Sampled	Expenditure Total
1	Cymbalta	Eli Lilly	Pharmaceutical	Depressive Disorder	4,221	$13,972.00
2	Viibryd*	Forest Laboratories	Pharmaceutical	Depressive Disorder	3,500	$54,441.00
3	Advair	GlaxoSmithKline	Pharmaceutical	Asthma	3,467	$31,221.00
4	Abilify	Bristol-Myers Squibb	Pharmaceutical	Schizophrenia	3,217	$27,724.00
5	Bystolic	Forest Pharmaceutical (subsidiary of Forest Laboratories)	Pharmaceutical	Hypertension	2,766	$2,096.00
6	Cialis	Eli Lilly	Pharmaceutical	Erectile Dysfunction	2,696	$14,472.00
7	Crestor	Astrazeneca	Pharmaceutical	Hyperlipidemia	2,667	$13,861.00
8	Nexium	Astrazeneca	Pharmaceutical	Gastroesophageal Reflux Disease	2,148	$8,263.00
9	Symbicort	Astrazeneca	Pharmaceutical	Asthma	1,842	$39,954.00
10	Namenda*	Forest Laboratories	Pharmaceutical	Alzheimer's Disease	1,545	$59,241.00
11	Intuniv	Shire	Pharmaceutical	Attention Deficit Hyperactivity Disorder	1,496	$2,575.22
12	Dexilant	Takeda Pharmaceutical America	Pharmaceutical	Erosive Esophagitis	1,476	$3,607.69
13	Savella	Forest Pharmaceutical (subsidiary of Forest Laboratories)	Pharmaceutical	Fibromyalgia	1,339	**
14	Benicar	Daiichi Sankyo	Pharmaceutical	Hypertension	1,288	$610.45
15	Vesicare	Astellas Pharma US	Pharmaceutical	Overactive Bladder	1,266	$13,060.00
16	Spiriva	Boehringer Ingelheim	Pharmaceutical	Chronic Obstructive Pulmonary Disease	1,259	$206.00
17	Celebrex	Pfizer	Pharmaceutical	Osteoarthritis	1,172	$311.85
18	Viagra	Pfizer	Pharmaceutical	Erectile Dysfunction	1,122	**
19	Colcrys	Takeda Pharmaceutical America	Pharmaceutical	Gout	1,053	**
20	Lyrica	Pfizer	Pharmaceutical	Neuropathic Pain	997	$3,500.00
21	Flovent	GlaxoSmithKline	Pharmaceutical	Asthma	969	$31,221.00
22	Unknown Products	LifeScan	Medical Device	Unknown	950	**
23	Seroquel XR	Astrazeneca	Pharmaceutical	Schizophrenia	879	**
24	Onglyza	Bristol-Myers Squibb	Pharmaceutical	Type 2 Diabetes	870	$1,940.00
25	Aciphex	Janssen Pharmaceutical	Pharmaceutical	Gastroesophageal Reflux Disease	846	$4,604.00
26	Nasonex	Merck Sharpe & Dhome	Pharmaceutical	Allergic Rhinitis	837	**
27	Daliresp*	Forest Laboratories	Pharmaceutical	Chronic Obstructive Pulmonary Disease	752	$88,932.00
28	Dulera	3M	Pharmaceutical	Asthma	739	$4,000.00

Exhibit 10b: Top Products - 50 Products with Greatest Number of Samples, 2012

Rank	Product Name	Manufacturer	Product Type	Primary Indication	Number of Times Sampled	Expenditure Total
29	Vimovo	Astrazeneca	Pharmaceutical	Osteoarthritis	664	**
30	Maxalt	Merck Sharpe & Dhome	Pharmaceutical	Migraine	663	$55.92
31	Januvia*	Merck Sharpe & Dhome	Pharmaceutical	Type 2 Diabetes	604	$102,663.58
32	Lunesta	Sunovion	Pharmaceutical	Insomnia	597	**
33	Livalo	Kowa Pharmaceutical America	Pharmaceutical	Hyperlipidemia	589	$1,000.00
34	1-Day Acuvue Moist	Johnson & Johnson Vision Care	Medical Device	Vision Correction	574	**
35	Cialis Daily	Eli Lilly	Pharmaceutical	Erectile Dysfunction	562	**
36	Ventolin	GlaxoSmithKline	Pharmaceutical	Bronchospasm	546	**
37	Tradjenta	Boehringer Ingelheim	Pharmaceutical	Type 2 Diabetes	541	$900.00
38	Levitra	GlaxoSmithKline	Pharmaceutical	Erectile Dysfunction	526	**
39	Vytorin*	Merck Sharpe & Dhome	Pharmaceutical	Hyperlipidemia	522	$988,409.00
40	NovoLog*	Novo Nordisk	Pharmaceutical	Type 2 Diabetes	513	$62,414.00
41	Test Strips	Abbott Laboratories	Medical Device	Blood Glucose Testing	491	**
42	Kombiglyze XR	Bristol-Myers Squibb	Pharmaceutical	Type 2 Diabetes	486	$8,287.00
43	Axiron	Eli Lilly	Pharmaceutical	Primary Hypogonadism	479	$500.00
44	Acuvue Oasys For Astigmatism	Johnson & Johnson Vision Care	Medical Device	Vision Correction	460	**
45	Chantix	Pfizer	Pharmaceutical	Smoking Cessation	449	$14,159.67
46	Zetia*	Merck Sharpe & Dhome	Pharmaceutical	Hyperlipidemia	426	$47,253.23
47	Geodon	Pfizer	Pharmaceutical	Schizophrenia	420	**
48	Toviaz	Pfizer	Pharmaceutical	Overactive Bladder	412	**
49	Staxyn	GlaxoSmithKline	Pharmaceutical	Erectile Dysfunction	402	**
50	Tasigna	Novartis	Pharmaceutical	Philadelphia Chromosome Positive Chronic Myeloid Leukemia	391	$13,796.00
	Totals:				**58,696**	**$1,659,251.61**

*This product was also among the 50 products associated with the greatest total expenditures (see Exhibit 10a).

**No expenditures were reported as having been associated with this product.

Note: For purposes of this exhibit, whwn manufacturers disclosed an expenditure in connection with several different products, or a sample containing several different products, the Attorney General's Office assigned the expenditure of sample to each of the products disclosed in connection with the expenditure or sample . Where applicable, primary indication is according to the FDA.

Exhibit 11a: Expenditures by Primary Indication of the 50 Products with the Greatest Expenditures, FY08-2012

2012 Rank	Primary Indication	FY08 Expenditure Total	FY09 Expenditure Total	FY10 Expenditure Total	FY11 Expenditure Total	2011 Expenditure Total	2012 Expenditure Total
1	Alzheimer's*	$188,966.05	$26,733.30			$59,589.86	$1,747,411.16
2	Hyperlipidemia*				$136,860.42	$155,765.61	$1,035,662.23
3	Rheumatoid Arthritis	$40,008.99	$16,101.26		$453,180.95	$512,350.88	$872,723.54
4	Diabetes (Type 2 or Types 1 and 2)*	$402,650.29	$249,462.85	$152,177.07	$897,401.99	$786,080.24	$527,306.47
5	Multiple Sclerosis	$124,341.09	$151,750.70	$109,014.36	$536,255.38	$399,286.08	$499,132.99
6	Cronic Obstructive Pulmonary Disease*	$34,824.52	$49,123.20				$345,494.00
7	Hepatitis C		$18,239.51		$69,775.00	$69,775.00	$145,568.88
8	Hemophilia A						$132,812.80
9	Idiopathic Pulmonary Fibrosis						$122,249.00
10	Neovascular (Wet) Age-Related Macular Degeneration						$112,259.00
11	Depression/Anxiety*	$242,730.07	$344,227.30	$126,245.53			$109,277.26
12	Noninvasive Patient Monitoring						$103,568.00
13	Nausea and Vomiting				$60,965.59	$66,490.83	$103,433.20
14	Coronary Disease						$103,046.84
15	Unknown*					$66,707.00	$99,505.20
16	Vision Correction						$91,937.00
17	Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer						$91,685.00
18	Angina						$90,943.00
19	Non-Hodgkin's Lymphoma						$77,778.73
20	Atrial Flutter						$67,997.00
21	Febrile Neutropenia						$57,726.02
22	Metastatic Colorectal Cancer			$18,416.45			$54,988.00
23	Bipolar Disorder and/or Schizophrenia*	$76,605.66	$145,028.09	$23,652.43	$446,506.05	$437,971.31	$54,836.26
24	Hypertension*	$259,220.41	$116,204.19	$25,268.07	$147,713.98	$279,658.93	$52,594.66
25	Acute Coronary Syndrome			$22,530.53			$51,341.00
26	Contraception			$17,809.00	$143,310.00	$227,792.52	$49,469.00
27	Chronic Kidney Disease						$48,179.67
28	Suture						$48,050.00
29	Anti-Vascular Anti-Cancer Agent						$47,101.00
30	Disc Disease						$43,718.00
**	Active Ulcerative Proctitis					$802,251.30	
**	Acute Bacterial Skin and Skin Structure Infections				$35,600.70		
**	Adjuvant Colon Cancer					$45,925.00	
**	Allergy	$30,218.92					

Exhibit 11a: Expenditures by Primary Indication of the 50 Products with the Greatest Expenditures, FY08-2012

2012 Rank	Primary Indication	FY08 Expenditure Total	FY09 Expenditure Total	FY10 Expenditure Total	FY11 Expenditure Total	2011 Expenditure Total	2012 Expenditure Total
**	Angle Glaucoma or Ocular Hypertension			$17,695.00			
**	Anticoagulant	$54,661.22	$60,528.23		$83,744.00		
**	Artificial Lens			$32,250.00			
**	Asthma	$53,903.52		$13,126.57	$45,057.59	$55,050.22	
**	Atrial Fibrillation					$50,722.39	
**	Attention-Deficit/Hyperactivity Disorder	$217,983.72	$139,257.97	$112,709.10	$131,420.40		
**	Bacterial Infections		$23,196.53				
**	Benign Prostatic Hyperplasia	$20,610.66	$23,004.64				
**	Bone Graft Substitute				$43,814.32		
**	Cardiac Arrhythmia				$31,119.00	$170,418.39	
**	Central Venous Access Device Dysfunction					$41,925.00	
**	Cholesterol	$163,450.25	$108,851.27		$449,484.05		
**	Chronic Iron Overload			$11,603.27			
**	Coronary Stent System				$43,437.50		
**	Cosmetic Treatment for Face			$12,375.00			
**	Crohn's Disease			$10,297.01			
**	Cycstic Fibrosis			$16,060.00		$41,925.00	
**	Deep Vein Thrombosis	$18,117.00		$18,154.00		$44,126.30	
**	Diabetes (Type 1 Only)	$42,653.25	$122,159.72				
**	Diagnostic Radiopaque Media			$18,750.00			
**	Dry Eye Disease			$17,666.00			
**	Electrophysiology				$72,604.75		
**	Emergency Assistance			$36,012.00			
**	End Stage Renal Disease			$14,344.00			
**	Endoscopic Vessel Harvesting					$46,010.93	
**	Exocrine Pancreatic Insufficiency					$804,251.30	
**	Fibromyalgia				$36,593.32	$62,789.86	
**	Gastroesophageal Reflux Disease		$23,229.53				
**	General Anesthesia				$445,479.05	$436,484.11	
**	Gout		$16,599.31				
**	Growth Hormone Deficiency				$127,479.00	$127,479.00	
**	H. Pylori Infection					$802,251.30	
**	HER2 Overexpressing Breast Cancer			$13,327.85			
**	HIV				$446,038.05	$436,695.68	
**	Human Papillomavirus				$38,198.85		
**	Hunter Syndrome			$14,344.00			

Exhibit 11a: Expenditures by Primary Indication of the 50 Products with the Greatest Expenditures, FY08-2012

2012 Rank	Primary Indication	FY08 Expenditure Total	FY09 Expenditure Total	FY10 Expenditure Total	FY11 Expenditure Total	2011 Expenditure Total	2012 Expenditure Total
**	Hypercholesterolemia					$440,728.93	
**	Idiopathic Thrombocytopenic Purpura			$17,120.20			
**	Imaging				$149,416.09	$96,993.09	
**	Laparoscopic Surgery				$63,305.33	$63,305.33	
**	Leads				$44,657.54	$77,987.43	
**	Major Depressive Disorder				$101,588.77	$45,393.95	
**	Migraines		$92,568.41	$54,792.08	$39,736.04		
**	Myeloma and/or Mantle Cell Lymphoma	$27,767.00	$21,906.00	$57,549.00			
**	Ocular Itching			$17,642.00			
**	Orthopaedic				$29,818.12	$101,358.00	
**	Osteoporosis	$20,097.73	$36,453.02				
**	Overactive Bladder		$49,555.94				
**	Pain	$58,568.93	$66,162.77	$29,698.92			
**	Parkinsons Disease		$19,546.67		$33,534.28		
**	Persistent Atrial Fibrillation or Atrial Flutter			$27,395.00			
**	Prevention of Postoperative IOP			$17,666.00			
**	Remote Patient Monitoring					$50,722.39	
**	Sleep Aid	$20,436.33					
**	Smoking Cessation			$16,448.54			
**	Stroke/Stroke Preventative	$23,110.66	$18,775.18		$38,977.03	$48,455.90	
**	Surgery				$33,409.93		
**	Systolic Dysfunction				$56,719.00	$83,066.69	
**	Thrombotic Cardiovascular Events			$12,285.58			
**	Treatment of Opioid Dependence		$16,388.00				
**	Ulcerative Colitis		$46,410.62	$14,533.25			
**	Unresectable or Metastatic Melanoma with BRAF Mutation					$41,925.00	
**	Unstable Angina					$70,266.00	
**	Urinary Incontinence				$62,785.11		
Totals:		**$2,120,926.27**	**$2,001,464.21**	**$1,118,957.81**	**$5,575,987.18**	**$8,149,976.55**	**$6,987,794.92**

* This indication was also among the indications associated with the top 50 products sampled in 2012. (See exhibit 11b)

** These indications are not associated with the 50 products with greatest expenditures for FY12.

Note: For puroposes of this exhibit, when manufacturers disclosed an expediture in connection with several different products, or a sample containing several different products, the Attorney General's Office assignd the expenditure or sample to each of the products disclosed in conection with the expenditure or sample. Where applicable, primary indication is as according to the FDA.

Exhibit 11b: Samples by Primary Indication of the top 50 Products with the Greatest Number of Samples, 2012

Rank	Primary Indication	Number of Times Sampled, 2011	Number of Times Sampled, 2012
1	Depressive Disorder*		7,721
2	Asthma*	7,562	7,017
3	Erectile Dysfunction	1,184	5,308
4	Bipolar Disorder and/or Schizophrenia*	1,261	4,516
5	Hyperlipidemia*	2300	4,204
6	Hypertension*		4,054
7	Diabetes (Type 2 or Types 1 and 2)*	1,365	3,014
8	Gastroesophageal Reflux Disease	634	2,994
9	Cronic Obstructive Pulmonary Disease*	993	2,011
10	Osteoarthritis	1,137	1,836
11	Overactive Bladder	841	1,678
12	Alzheimer's Disease		1545
13	Attention-Deficit/Hyperactivity Disorder	1,147	1,496
14	Erosive Esophagitis	1,572	1,476
15	Fibromyalgia		1,339
16	Gout		1,053
17	Eye Care	1,780	1,034
18	Neuropathic Pain Associated with Diabetic Peripheral Neuropathy	721	997
19	Unknown*	1,436	950
20	Allergic Rhinitis	1,608	837
21	Migraine Headaches	839	663
22	Insomnia		597
23	Bronchospasm		546
24	Blood Glucose Testing		491
25	Primary Hypogonadism		479
26	Smoking Cessation		449
27	Chromosome Positive Chronic Myeloid Leukemia		391
**	Acute Coronary Syndrome	710	
**	Antipsychotic	3,206	

Exhibit 11b: Samples by Primary Indication of the top 50 Products with the Greatest Number of Samples, 2012

Rank	Primary Indication	Number of Times Sampled, 2011	Number of Times Sampled, 2012
**	Gout	1,228	
**	Hypothyroidism	1,025	
**	Myocardial Infarction Preventative	3,016	
**	Nutrition	2,219	
**	Vision Correction	27,887	
Totals:		**65,671**	**58,696**

* This indication was also among the indications associated with the top 50 products by expenditures in 2012. (See Exhibit 11a)

Exhibit 12: Expenditures by Payment Nature with Breakdown of "Other", 2012

Payment Nature	Expenditure Total	Number of Expenditures	Number of Recipients
Cash, Check or Credit Card	$6,496,826.54	1,778	283
Educational Materials	$805,508.51	2,505	480
Demo/Evaluation Unit	$281,807.72	311	94
Other	$23,762.90	286	174
Loan of Medical Device	$21,739.00	179	28
Totals:	**$7,629,644.67**	**72,755**	

Other Payment Nature	Expenditure Total	Number of Expenditures
Product	$11,129.80	117
Other Educational Materials/Benefits	$9,538.17	124
Gift	$955.76	9
(Left Blank)	$854.60	18
Food	$680.57	16
Other	$604.00	2
Totals:	**$23,762.90**	**286**

Exhibit 13: Expenditures by Payment Purpose with Breakdown of "Other Fair Market Value Payment" and "Other", 2012

Purpose of Payment	Expenditure Total	Number of Expenditures	Number of Recipients
Bona fide Clinical Trial	$3,713,394.81	561	37
(Gross Compensation)	$3,457,627.51	472	28
(Expenses)	$139,872.43	72	14
(Salary Support)	$115,894.87	17	4
Research Project	$1,290,815.44	35	7
(Gross Compensation)	$1,255,513.44	29	7
(Expenses)	$35,302.00	6	2
Educational Materials	$801,369.99	2,509	483
Consulting	$356,485.36	178	50
Medical Device - Loans, Demos	$303,546.72	490	106
Faculty Honoraria/Speaker Fee	$251,466.00	132	33
Other Fair Market Value Payment	$223,148.34	261	67
Scholarship	$185,734.80	5	2
Conference Sponsorship	$156,729.00	80	26
Other	$112,437.44	230	71
Gift to Institution/Organization	$103,484.60	13	8
Medical Device Training	$73,245.25	423	215
(Other Expenses)	$67,016.08	416	210
(Compensation)	$6,229.17	7	7
Faculty Expense	$57,786.91	142	21
Totals	**$7,629,644.67**	**5,059**	

Exhibit 13: Expenditures by Payment Purpose with Breakdown of "Other Fair Market Value Payment" and "Other", 2012

Other Fair Market Value Payment Description	Expenditure Total	Number of Expenditures
Speaker Fees/Expenses	$114,066.76	100
Booth/Exhibit Fee	$87,605.00	106
Membership fee	$10,000.00	1
Speaker Training	$3,775.00	2
Surgical Training	$2,500.00	1
Patient Training	$2,467.00	9
(Left Blank)	$1,689.69	20
Meal	$794.89	21
Credentialing Fee	$250.00	1
Totals:	**$223,148.34**	**261**

Other Purpose of Payment	Expenditure Total	Number of Expenditures
Medical Education Grant	$62,185.00	5
Charitable Contribution	$19,753.17	5
Gift	$11,955.00	2
Other Travel/Meal	$6,854.73	23
Other Travel	$5,303.00	11
Other	$2,152.00	9
Product Donation-Educational Program	$1,303.80	1
Meal	$935.66	34
Free Distribution to Patients	$871.00	115
Marketing	$454.08	5
(Left Blank)	$334.00	17
Investigator Meeting	$174.00	1
Other Speaker Compensation/Expenses	$162.00	2
Totals:	**$112,437.44**	**230**

Exhibit 14a: Minimum Clinical Trial Information, January 1, 2012 - December 31, 2012

	Trial Name	Start Date	Manufacturer	Link to National Clinical Trial Registry
1	Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)	Apr-06	Medtronic	http://clinicaltrials.gov/ct2/show/NCT00354159
2	A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients with Inflammatory Bowel Disease	May-07	Janssen Biotech	http://clinicaltrials.gov/ct2/show/NCT00606346?term=A+Multi-Center%2C+Prospective%2C+Long-term%2C+Observational+Registry+of+Pediatric+Patients+with+Inflammatory+Bowel+Disease&rank=1
3	Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's Disease	Jan-08	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT00335153?term=00335153&rank=1
4	A Randomized, Double-Blind, Placebo-Controlled, Event-Driven Multicenter Study to Evaluate the Efficacy and Safety of Rivaroxaban in Subjects With a Recent Acute Coronary Syndrome	Nov-08	Janssen Research & Development	http://clinicaltrials.gov/ct2/show/NCT00809965?term=Rivaroxaban+AND+acute+coronary+syndrome&rank=1
5	A Phase 2, Multicenter, Multinational, Randomized, Double-blind, Placebo controlled, Parallel-group, Dose-ranging Study Evaluating the Efficacy and Safety of CNTO 888 Administered Intravenously in Subjects with Idiopathic Pulmonary Fibrosis	Dec-08	Janssen Research & Development	http://clinicaltrials.gov/ct2/show/NCT00786201?term=cnto888+AND+pulmonary+fibrosis&rank=1
6	Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects	Jan-09	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT00357994?term=NCT00357994&rank=1
7	Long-Term Safety and Efficacy Study of Oral BG00012 Monotherapy in Relapsing-Remitting Multiple Sclerosis	Feb-09	Biogen Idec	http://clinicaltrials.gov/ct2/show/NCT00835770?term=biogen+idec%2C+109MS303&rank=1
8	Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects	Jun-09	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT00360568?term=00360568&rank=1
9	SPIRIT PRIME Clinical Trial	Jun-09	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT00916370?term=NCT00916370&rank=1
10	A Double-Blind, Placebo-Controlled Study of Cariprazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder	Jun-09	Forest Laboratories	http://clinicaltrials.gov/ct2/show/NCT00854100?spons=%22Forest+Laboratories%22&spons_ex=Y&state1=NA%3AUS%3AVT&rank=1
11	A Double-blind, Placebo-controlled Study of RGH-188 (Cariprazine) in Bipolar Depression	Jun-09	Forest Laboratories	http://clinicaltrials.gov/ct2/show/NCT00852202?spons=%22Forest+Laboratories%22&spons_ex=Y&state1=NA%3AUS%3AVT&rank=3

Exhibit 14a: Minimum Clinical Trial Information, January 1, 2012 - December 31, 2012

12	A Double-blind, Placebo-Controlled, Flexible-Dose Study of F2695 SR in Patients With Major Depressive Disorder	Sep-09	Forest Laboratories	http://clinicaltrials.gov/ct2/show/NCT00969150?spons=%22Forest+Laboratories%22&spons_ex=Y&state1=NA%3AUS%3AVT&rank=7
13	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of VX-770 in Subjects Aged 12 Years and Older With Cystic Fibrosis who are Homozygous for the F508del-CFTR Mutation	Sep-09	Vertex Pharmaceuticals	http://www.clinicaltrials.gov/ct2/show/NCT00953706?term=vx-770&rank=9
14	ACT-128800 in Relapsing-remitting Multiple Sclerosis	Oct-09	Actelion	http://clinicaltrials.gov/ct2/show/NCT01006265?term=actelion+and+ms&rank=2
15	Extension Phase of the Chronicle® Offers Management to Patients With Advanced Signs & Symptoms of Heart Failure Study [COMPASS-HF]	Oct-09	Medtronic	http://clinicaltrials.gov/ct2/show/NCT00991120
16	Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced PD	Nov-09	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT00660673?term=00660673&rank=1
17	A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis	Nov-09	Janssen Research & Development	http://clinicaltrials.gov/ct2/show/study/NCT00955279?term=1275148-SCD-2001&rank=1#locn
18	Adaptive Cardiac Resynchronization Therapy Study (aCRT)	Nov-09	Medtronic	http://clinicaltrials.gov/ct2/show/NCT00980057
19	Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects	Dec-09	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT00660387?term=NCT00660387&rank=1
20	A Long-Term, Open-label Extension Study of F2695 SR in Adult Patients With Major Depressive Disorder	Dec-09	Forest Laboratories	http://clinicaltrials.gov/ct2/show/NCT01034267?spons=%22Forest+Laboratories%22&spons_ex=Y&state1=NA%3AUS%3AVT&rank=11
21	A Study With Aleglitazar in Patients With a Recent Acute Coronary Syndrome and Type 2 Diabetes Mellitus	Jan-10	Genentech	http://clinicaltrial.gov/ct2/show/NCT01042769?term=NCT01042769&rank=1
22	JCV Antibody Program (STRATIFY-2)	Apr-10	Biogen Idec	http://clinicaltrials.gov/ct2/show/NCT01070836?term=101JC402&rank=1

Exhibit 14a: Minimum Clinical Trial Information, January 1, 2012 - December 31, 2012

23	EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events	Apr-10	Medtronic	http://clinicaltrials.gov/ct2/show/NCT01069003
24	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Heart Failure (Defeat-HF)	Apr-10	Medtronic	http://clinicaltrials.gov/ct2/show/NCT01112579
25	ACT-128800 in Relapsing-remitting Multiple Sclerosis - Extension Study	May-10	Actelion	http://clinicaltrials.gov/ct2/show/NCT01093326?term=NCT01093326&rank=1
26	Efficacy and Safety of Daclizumab High Yield Process Versus Interferon β 1a in Patients With Relapsing-Remitting Multiple Sclerosis ((DECIDE))	May-10	Biogen Idec	http://clinicaltrials.gov/ct2/show?term=205ms301&rank=2
27	28431754DIA3002: A Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sulphonylurea Therapy - The CANTATA-MSU Trial	May-10	Janssen Research & Development	http://clinicaltrials.gov/ct2/show/NCT01106625?term=28431754-DIA-3002&rank=1
28	Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide) (ELIXA)	Jun-10	Sanofi	http://www.clinicaltrials.gov/ct2/show/NCT01147250?term=EFC11319&rank=1
29	Evaluation of the WATCHMAN LAA Closure Device in Patients with Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL)	Nov-10	Boston Scientific	http://www.clinicaltrials.gov/ct2/show/study/NCT01182441
30	A Study of Gantenerumab in Patients With Prodromal Alzheimer's Disease	Nov-10	Genentech	http://clinicaltrials.gov/ct2/show/NCT01224106?term=NCT01224106&rank=1
31	An Open Label Study of Abiraterone Acetate in Subjects With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed After Taxane-Based Chemotherapy	Nov-10	Janssen Research & Development	http://clinicaltrials.gov/ct2/show/NCT01217697?term=NCT01217697&rank=1

Exhibit 14a: Minimum Clinical Trial Information, January 1, 2012 - December 31, 2012

32	Safety and Efficacy Study of the Medtronic CoreValve® System in the Treatment of Symptomatic Severe Aortic Stenosis in High Risk and Very High Risk Subjects Who Need Aortic Valve Replacement [CoreValve]	Nov-10	Medtronic	http://clinicaltrials.gov/ct2/show/NCT01240902
33	A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists	Feb-11	Genentech	http://clinicaltrial.gov/ct2/show/NCT01264939?term=Q4883g&rank=1
34	A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)	Feb-11	Genentech	http://clinicaltrials.gov/ct2/show/NCT01278134?term=NCT01278134&rank=1
35	Evaluate the Efficacy and Safety of Once Daily Administration of Atrasentan Tablets (Low and High) Compared to Placebo in Reducing Residual Albuminuria in Type 2 Diabetic Patients With Nephropathy Who Are Treated With the Maximum Tolerated Labeled Dose of a Renin Angiotensin System (RAS) Inhibitor (RADAR)	Apr-11	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT01356849?term=NCT01356849&rank=1
36	SuperNOVA Clinical Stenting Trial	Apr-11	Boston Scientific	http://clinicaltrial.gov/ct2/show/NCT01292928
37	A Study to Evaluate the Efficacy and Safety of MABT5102A in Patients With Mild to Moderate Alzheimer's Disease (ABBY)	Apr-11	Genentech	http://clinicaltrial.gov/ct2/show/NCT01343966?term=NCT01343966&rank=1
38	BMS 820836-010: A Multicenter, Double-Blind, 58 Week Rollover Study to Assess the Safety and Tolerability of BMS-820836 in Patients With Treatment Resistant Major Depression	May-11	Bristol-Myers Squibb	http://clinicaltrials.gov/ct2/show/NCT01361555?lead=Bristol+Myers+Squibb&state1=NA%3AUS%3AVT&rank=11

Exhibit 14a: Minimum Clinical Trial Information, January 1, 2012 - December 31, 2012

39	A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 (three doses) for the Treatment of active, Non-Infectious Uveitis of the Posterior Segment of the eye	May-11	Santen	http://clinicaltrials.gov/ct2/show/NCT01358266
40	BMS 820836-007: A Multicenter, Randomized, Double-Blind, Active Controlled, Comparative, Fixed-Dose, Dose Response Study of the Efficacy and Safety of BMS-820836 in Patients With Treatment Resistant Major Depression (TRD).	Jun-11	Bristol-Myers Squibb	http://clinicaltrials.gov/ct2/show/NCT01369095?lead=Bristol+Myers+Squibb&state1=NA%3AUS%3AVT&rank=12
41	A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Patients With Relapsing Multiple Sclerosis	Aug-11	Genentech	http://clinicaltrial.gov/ct2/show/NCT01247324?term=NCT01247324&rank=1
42	The OMEGA Clinical Trial	Oct-11	Boston Scientific	http://clinicaltrials.gov/ct2/show/NCT01419171
43	A Phase 2, Multicenter, Double-Blinded, Placebo Controlled, 3-Part Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 Monotherapy and VX-661/VX-770 Cotherapy in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation	Feb-12	Vertex Pharmaceuticals	http://www.clinicaltrials.gov/ct2/show/study/NCT01531673?term=VX11-661-101&rank=1
44	Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors	Mar-12	Abbott	http://www.clinicaltrials.gov/ct2/show/NCT01549834?term=NCT01549834&rank=1
45	191-092 - A 12-week Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study to Replicate Efficacy of Nebulized Fluticasone Propionate (FP) in Adult Subjects with Partly Controlled and Uncontrolled Asthma	Mar-12	Mylan Specialty	http://clinicaltrials.gov/ct2/show/NCT01516086?term=191-092&rank=1
46	A Phase 3, Multicenter, Randomized, Double-blind, Vehicle-controlled Study to Evaluate the Safety and Efficacy of Product 55394 in the Treatment of Bacterial Vaginosis	May-12	Valeant Pharmaceuticals North America	http://clinicaltrials.gov/show/NCT01621399

Exhibit 14a: Minimum Clinical Trial Information, January 1, 2012 - December 31, 2012

47	A Phase 2, randomized, double-dummy, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of AVP-923 (dextromethorphan/quinidine) for the treatment of symptoms of agitation in patients with Alzheimer's disease	Jun-12	Avanir Pharmaceuticals	http://www.clinicaltrial.gov/ct2/show/NCT01584440?term=12-AVR-131&rank=1
48	ANNAPURNA: A Study of The Combination of RO5466731, RO5190591, Ritonavir and Copegus (Ribavirin) With or Without RO5024048 in Patients With Chronic Hepatitis C Who Are Either Treatment-Naïve or Have Previously Experienced a Null Response to Interferon-Based Treatment	Jun-12	Genentech	http://clinicaltrials.gov/ct2/show/NCT01628094?term=NP28266&rank=1
49	A Phase 2, Multicenter, Single-Arm, Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy	Aug-12	Janssen Research & Development	http://clinicaltrials.gov/ct2/show/NCT01599949?term=NCT01599949&rank=1
50	A Long-Term Safety Extension Study of Studies ABE4869g And ABE4955g in Patients With Mild To Moderate Alzheimer's Disease Treated With Crenezumab	Dec-12	Genentech	http://clinicaltrial.gov/ct2/show/NCT01723826?term=ABE4869g&rank=1

Exhibit 14b: Delayed Clinical Trial Disclosures, 2012

Manufacturer	Recipient(s)	Expenditure Date Range	Expenditure Total	Product Type	Product Name	Indication
Eli Lilly	Hospital/Laboratory/Doctor	2009-2011	$870,657.00	Pharmaceutical	Solanezumab	n/a
Forest Laboratories	Doctor	2009-2011	$253,300.00	Pharmaceutical	Tudorza	Chronic Obstructive Pulmonary Disease
Genzyme	Hospital/Doctor	2009-2011	$200,821.00	Pharmaceutical	Aubagio	Multiple Sclerosis
Medtronic	Hospital/Registered Nurse	2010-2011	$103,046.84	Medical Device	Coronary Stent	Disease
Eli Lilly	Hospital/Laboratory	2009-2011	$79,935.00	Pharmaceutical	Alimta	Mesothelioma
Eli Lilly	Laboratory	2009-2011	$71,245.30	Pharmaceutical	LY451395	n/a
Eli Lilly	Laboratory	2009-2011	$54,836.26	Pharmaceutical	Symbyax	Bipolar Disorder
Sanofi-Aventis US	Hospital/Laboratory	2009-2010	$54,668.00	Biologic	Zaltrap	Colorectal Cancer
Sanofi-Aventis US	Hospital	2009-2010	$38,710.00	Pharmaceutical	Nerispirdine	n/a
Genentech	Hospital	2011	$14,872.66	Pharmaceutical	Taspoglutide	n/a
Biogen Idec	Doctor	2008	$9,464.00	Biologic	109-MS-302	n/a
Eli Lilly	Doctor	2009	$8,030.49	Pharmaceutical	LY2216684	n/a
Genentech	Hospital	2011	$5,900.00	Biologic	Bevacizumab	Colorectal Cancer
Sanofi-Aventis US	Laboratory	2011	$5,000.00	Biologic	Semuloparin	n/a
Sanofi-Aventis US	Laboratory	2011	$4,500.00	Pharmaceutical	SAR231893	n/a
Genentech	Hospital	2011	$3,000.00	Biologic	Pulmozyme	n/a
Biogen Idec	Doctor	2008	$2,500.00	Biologic	109-MS-301	n/a
Eli Lilly	Hospital	2011	$2,500.00	Pharmaceutical	LY2127399	n/a
Sanofi-Aventis US	Laboratory	2010	$660.00	Pharmaceutical	Larotaxel	n/a

Total: **$1,783,646.55**

Exhibit 15: Contents of Sample by Category with Breakdown of "Other", 2012



Other Sample Type	Sample Description	Total Number of Samples
Educational Material		7,253
Non-Prescribed Item		1,119
Other (Total)		1,595
Other:	Kit/Kit Component	538
Other:	Carrying Case/User Pack	451
Other:	Instruction Sheet/Guide	130
Other:	Warranty Registration Card	127
Other:	Prescription Stickers	124
Other:	Patient Claim Envelope	78
Other:	Log Book	54
Other:	Lens Case and Product Insert	40
Other:	Free Trial Product	23
Other:	Ice refrigerant/Insulated Container	12
Other:	Wall Charger, USB Cable, Meter Tray	12
Other:	(Left Blank)	4
Other:	Fitting Software	1
Other:	Wallet card	1